SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-3.13%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$782M
AUM Growth
+$782M
(-6.9%)
Cap. Flow
-$20.5M
Cap. Flow
% of AUM
-2.62%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
11
New
–
Increased
1
Reduced
3
Closed
–
Top Buys
| 1 |
AMRN
Amarin Corp
AMRN
|
$155K |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$18.1M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$1.71M |
| 3 |
Mersana Therapeutics
MRSN
|
$810K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alkermes
ALKS
$4.78B
| $253M | 32.32% | 8,964,640 | – | – |
|
2
Biogen
BIIB
$19.4B
| $179M | 22.86% | 643,000 | – | – |
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $172M | 22.05% | 16,390,000 | – | – |
|
4
Innoviva
INVA
$1.29B
| $74.4M | 9.52% | 6,614,000 | – | – |
|
|
5
Gilead Sciences
GILD
$140B
| $70.5M | 9.02% | 850,000 -218,750 | -20% | -$18.1M |
|
|
6
Mersana Therapeutics
MRSN
$36.5M
| $15.6M | 2% | 3,800,000 -197,010 | -5% | -$810K |
|
|
AMRN
7
Amarin Corp
AMRN
$311M
| $7.37M | 0.94% | 4,910,000 +103,000 | +2% | +$155K |
|
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.46M | 0.83% | 775,000 -205,288 | -21% | -$1.71M |
|
9
Vor Biopharma
VOR
$250M
| $3.32M | 0.43% | 618,000 | – | – |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $157K | 0.02% | 185,183 | – | – |
|
|
PEAR
11
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $128K | 0.02% | 500,356 | – | – |
|